Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 May;71(5):1099–1105. doi: 10.1038/bjc.1995.213

Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas.

S Rehn 1, J S Gronowitz 1, C Källander 1, C Sundström 1, B Glimelius 1
PMCID: PMC2033808  PMID: 7734308

Abstract

The levels of deoxythymidine kinase in tumour cells (C-TK) and in serum (S-TK) were investigated and the tumour volume calculated in 89 patients with non-Hodgkin lymphoma (NHL), in order to ascertain the importance of C-TK and tumour burden as regards the S-TK levels. Among all patients, a correlation was seen between S-TK and tumour volume but not between S-TK and C-TK. However, within different tumour volume categories (small, medium-sized and large), there was a correlation between S-TK and C-TK. Multiple regression analysis supported this notion. C-TK correlated with the proliferation-associated parameters, S-phase fraction and mitotic index. As already known, S-TK was found to have a strong prognostic value. C-TK and tumour burden were also of prognostic value. In multivariate analyses, C-TK and tumour volume did not provide prognostic information in addition to S-TK, whereas, in the absence of S-TK, C-TK and tumour volume did provide additional information. It is concluded that the serum level of TK depends on both the tumour burden and the tumour cell proliferation rate. Based upon estimations of S-TK in patients assessed shortly after chemotherapy, we also suggest that S-TK reflects the number of proliferating cells that have died during the period immediately before sampling.

Full text

PDF
1100

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akerman M., Brandt L., Johnson A., Olsson H. Mitotic activity in non-Hodgkin's lymphoma. Relation to the Kiel classification and to prognosis. Br J Cancer. 1987 Feb;55(2):219–223. doi: 10.1038/bjc.1987.41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Archimbaud E., Vigreux B., Tigaud J. D., Maupas J., Guyotat D., Viala J. J., Fiere D. Serum thymidine kinase in acute nonlymphoblastic leukemia. Leukemia. 1988 Apr;2(4):245–246. [PubMed] [Google Scholar]
  3. Carbone P. P., Kaplan H. S., Musshoff K., Smithers D. W., Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971 Nov;31(11):1860–1861. [PubMed] [Google Scholar]
  4. Catalano L., Frigeri F., Camera A., De Rosa G., Festinese R., Rotoli B. Kinetics of serum TK and LDH during therapy for AML. Haematologica. 1990 May-Jun;75(3):301–303. [PubMed] [Google Scholar]
  5. Ellims P. H., Eng Gan T., Medley G., Van Der Weyden M. B. Prognostic relevance of thymidine kinase isozymes in adult non-Hodgkin's lymphoma. Blood. 1981 Nov;58(5):926–930. [PubMed] [Google Scholar]
  6. Eriksson B., Hagberg H., Glimelius B., Sundström C., Gronowitz S., Källander C. Serum thymidine kinase as a prognostic marker in Hodgkin's disease. Acta Radiol Oncol. 1985 Mar-Apr;24(2):167–171. doi: 10.3109/02841868509134381. [DOI] [PubMed] [Google Scholar]
  7. Francavilla A., Panella C., Polimeno L., Giangaspero A., Mazzaferro V., Pan C. E., Van Thiel D. H., Starzl T. E. Hormonal and enzymatic parameters of hepatic regeneration in patients undergoing major liver resections. Hepatology. 1990 Nov;12(5):1134–1138. doi: 10.1002/hep.1840120510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gan T. E., Finch P. D., Brumley J. L., Hallam L. J., van der Weyden M. B. Pyrimidine and purine activities in non-Hodgkin's lymphoma. Correlation with histological status and survival. Eur J Cancer Clin Oncol. 1984 Mar;20(3):361–368. doi: 10.1016/0277-5379(84)90082-8. [DOI] [PubMed] [Google Scholar]
  9. Gronowitz J. S., Hagberg H., Källander C. F., Simonsson B. The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma. Br J Cancer. 1983 Apr;47(4):487–495. doi: 10.1038/bjc.1983.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gronowitz J. S., Källander F. R., Diderholm H., Hagberg H., Pettersson U. Application of an in vitro assay for serum thymidine kinase: results on viral disease and malignancies in humans. Int J Cancer. 1984 Jan 15;33(1):5–12. doi: 10.1002/ijc.2910330103. [DOI] [PubMed] [Google Scholar]
  11. Gronowitz J. S., Steinholtz L., Källander C. F., Hagberg H., Bergh J. Serum deoxythymidine kinase in small cell carcinoma of the lung. Relation to clinical features, prognosis, and other biochemical markers. Cancer. 1986 Jul 1;58(1):111–118. doi: 10.1002/1097-0142(19860701)58:1<111::aid-cncr2820580120>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  12. Hagberg H., Glimelius B., Gronowitz S., Killander A., Källander C., Schröder T. Biochemical markers in non-Hodgkin's lymphoma stages III and IV and prognosis: a multivariate analysis. Scand J Haematol. 1984 Jul;33(1):59–67. doi: 10.1111/j.1600-0609.1984.tb02211.x. [DOI] [PubMed] [Google Scholar]
  13. Hagberg H., Gronowitz S., Killander A., Källander C. Serum thymidine kinase in vitamin B12 deficiency. Scand J Haematol. 1984 Jan;32(1):41–45. doi: 10.1111/j.1600-0609.1984.tb00675.x. [DOI] [PubMed] [Google Scholar]
  14. Hagberg H., Gronowitz S., Killander A., Källander C., Simonsson B., Sundström C., Oberg G. Serum thymidine kinase in acute leukaemia. Br J Cancer. 1984 Apr;49(4):537–540. doi: 10.1038/bjc.1984.82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Klimo P., Connors J. M. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med. 1985 May;102(5):596–602. doi: 10.7326/0003-4819-102-5-596. [DOI] [PubMed] [Google Scholar]
  16. Lehtinen M., Wigren T., Lehtinen T., Kallioniemi O. P., Aine R., Aaran R. K., Ojala A. Correlation between serum tumor marker levels and tumor proliferation in small cell lung cancer. Tumour Biol. 1988;9(6):287–292. doi: 10.1159/000217574. [DOI] [PubMed] [Google Scholar]
  17. Leonard R. C., Cuzick J., MacLennan I. C., Vanhegan R. I., Mackie P. H., McCormick C. V. Prognostic factors in non-Hodgkin's lymphoma: the importance of symptomatic stage as an adjunct to the Kiel histopathological classification. Br J Cancer. 1983 Jan;47(1):91–102. doi: 10.1038/bjc.1983.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lewenhaupt A., Ekman P., Eneroth P., Nilsson B. Tumour markers as prognostic aids in prostatic carcinoma. Br J Urol. 1990 Aug;66(2):182–187. doi: 10.1111/j.1464-410x.1990.tb14900.x. [DOI] [PubMed] [Google Scholar]
  19. Luoni R., Ucci G., Riccardi A., Gobbi P., Avato F. M., Vignale C., Ascari E. Serum thymidine kinase in monoclonal gammopathies. A prospective study. The Cooperative Group for Study and Treatment of Multiple Myeloma. Cancer. 1992 Mar 15;69(6):1368–1372. doi: 10.1002/1097-0142(19920315)69:6<1368::aid-cncr2820690611>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  20. Martinsson U., Glimelius B., Hagberg H., Simonsson B., Sundström C. Intracytoplasmic immunoglobulins in the differential diagnosis of lymphocytic lymphomas of the B-CLL type and immunocytic lymphomas. Acta Radiol Oncol. 1985 Nov-Dec;24(6):527–535. doi: 10.3109/02841868509134427. [DOI] [PubMed] [Google Scholar]
  21. Martinsson U., Glimelius B., Hagberg H., Sundström C. Prognostic relevance of serum-markers in relation to histopathology, stage and initial symptoms in advanced low-grade non-Hodgkin lymphomas. Eur J Haematol. 1988 Apr;40(4):289–298. doi: 10.1111/j.1600-0609.1988.tb00180.x. [DOI] [PubMed] [Google Scholar]
  22. McKenna P. G., O'Neill K. L., Abram W. P., Hannigan B. M. Thymidine kinase activities in mononuclear leukocytes and serum from breast cancer patients. Br J Cancer. 1988 Jun;57(6):619–622. doi: 10.1038/bjc.1988.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Nakao K., Fujioka S. Thymidine kinase activity in the human bone marrow from various blood diseases. Life Sci. 1968 Apr 15;7(8):395–399. doi: 10.1016/0024-3205(68)90039-8. [DOI] [PubMed] [Google Scholar]
  24. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976 Dec;34(6):585–612. doi: 10.1038/bjc.1976.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Polimeno L., Azzarone A., Dell'Aquila P., Amoruso C., Barone M., Angelini A., Van Thiel D. H., Francavilla A. Relationship between plasma and hepatic cytosolic levels of ornithine decarboxylase (ODC) and thymidine kinase (TK) in 70% hepatectomized rats. Dig Dis Sci. 1991 Mar;36(3):289–292. doi: 10.1007/BF01318198. [DOI] [PubMed] [Google Scholar]
  26. Rehn S. M., Nyman R. S., Glimelius B. L., Hagberg H. E., Sundström J. C. Non-Hodgkin lymphoma: predicting prognostic grade with MR imaging. Radiology. 1990 Jul;176(1):249–253. doi: 10.1148/radiology.176.1.2353098. [DOI] [PubMed] [Google Scholar]
  27. Rehn S., Glimelius B., Strang P., Sundström C., Tribukait B. Prognostic significance of flow cytometry studies in B-cell non-Hodgkin lymphoma. Hematol Oncol. 1990 Jan-Feb;8(1):1–12. doi: 10.1002/hon.2900080102. [DOI] [PubMed] [Google Scholar]
  28. Rehn S., Glimelius B., Sundström C. A comparative study of proliferation-associated parameters in B-cell non-Hodgkin lymphoma. Hematol Oncol. 1991 Nov-Dec;9(6):287–298. doi: 10.1002/hon.2900090603. [DOI] [PubMed] [Google Scholar]
  29. Robertson J. F., O'Neill K. L., Thomas M. W., McKenna P. G., Blamey R. W. Thymidine kinase in breast cancer. Br J Cancer. 1990 Oct;62(4):663–667. doi: 10.1038/bjc.1990.352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Romain S., Javre J. L., Samperez S., Jouan P., Bressac C., Varette I., Brandone H., Martin P. M. Valeur pronostique de la thymidine kinase dans le cancer du sein. Bull Cancer. 1990;77(10):973–983. [PubMed] [Google Scholar]
  31. Sherley J. L., Kelly T. J. Regulation of human thymidine kinase during the cell cycle. J Biol Chem. 1988 Jun 15;263(17):8350–8358. [PubMed] [Google Scholar]
  32. Simonsson B., Källander C. F., Brenning G., Killander A., Gronowitz J. S., Bergström R. Biochemical markers in multiple myeloma: a multivariate analysis. Br J Haematol. 1988 May;69(1):47–53. doi: 10.1111/j.1365-2141.1988.tb07601.x. [DOI] [PubMed] [Google Scholar]
  33. Tubiana M., Carde P., Burgers J. M., Cosset J. M., Van Glabbeke M., Somers R. Prognostic factors in non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 1986 Apr;12(4):503–514. doi: 10.1016/0360-3016(86)90057-x. [DOI] [PubMed] [Google Scholar]
  34. Vertongen F., Fondu P., van den Heule B., Cauchie C., Mandelbaum I. M. Thymidine kinase and thymidine phosphorylase activities in various types of leukaemia and lymphoma. Tumour Biol. 1984;5(6):303–311. [PubMed] [Google Scholar]
  35. Wooldridge T. N., Grierson H. L., Weisenburger D. D., Armitage J. O., Sanger W. G., Collins M. M., Pierson J. L., Pauza M. E., Fordyce R., Purtilo D. T. Association of DNA content and proliferative activity with clinical outcome in patients with diffuse mixed cell and large cell non-Hodgkin's lymphoma. Cancer Res. 1988 Nov 15;48(22):6608–6613. [PubMed] [Google Scholar]
  36. Young G. A., Hedley D. W., Rugg C. A., Iland H. J. The prognostic significance of proliferative activity in poor histology non-Hodgkin's lymphoma: a flow cytometry study using archival material. Eur J Cancer Clin Oncol. 1987 Oct;23(10):1497–1504. doi: 10.1016/0277-5379(87)90092-7. [DOI] [PubMed] [Google Scholar]
  37. van der Gaast A., van Putten W. L., Oosterom R., Cozijnsen M., Hoekstra R., Splinter T. A. Prognostic value of serum thymidine kinase, tissue polypeptide antigen and neuron specific enolase in patients with small cell lung cancer. Br J Cancer. 1991 Aug;64(2):369–372. doi: 10.1038/bjc.1991.309. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES